|
Title
|
|
|
|
The activity of raltitrexed (Tomudex ®) in malignant pleural mesothelioma: an EORTC phase II study (08992)
|
|
|
Author
|
|
|
|
|
|
|
Institution/Organisation
|
|
|
|
EORTC Lung Canc Grp
|
|
|
Abstract
|
|
|
|
| We investigated the activity and toxicity of raltitrexed (Tomudex(R)) as a single agent treatment in patients with Malignant Pleural Mesothelioma (MPM) in a multicentre phase II European Organization for Research and Treatment of Cancer (EORTC) study, This study enrolled chemonaive patients with histologically-confirmed measurable MPM. Raltitrexed was administered at the dose of 3 mg/m(2) intravenous (i.v.) bolus on an outpatient basis every 3 weeks. A maximum of eight cycles was planned in cases with an absence of progression or unacceptable toxicity. 24 patients received a total of 104 courses. 5 patients (20.8%, 95% confidence interval (CI) 7.1-42.2%) had a partial response (PR), which was confirmed by an independent radiology committee. Toxicity was mild, with diarrhoea, nausea, vomiting, fatigue and neutropenia as the major side-effects, but not exceeding grade 3 toxicity. We conclude that raltitrexed has activity as a single agent in the treatment of MPM, and that further studies with this drug in MPM are warranted. (C) 2003 Elsevier Science Ltd. All rights reserved. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
European journal of cancer. - Oxford, 1990, currens
|
|
|
Publication
|
|
|
|
Oxford
:
2003
|
|
|
ISSN
|
|
|
|
0959-8049
[print]
1879-0852
[online]
|
|
|
DOI
|
|
|
|
10.1016/S0959-8049(02)00668-8
|
|
|
Volume/pages
|
|
|
|
39
:3
(2003)
, p. 353-357
|
|
|
ISI
|
|
|
|
000181226700020
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|